NASDAQ: ABEOAbeona Therapeutics Inc Stock
$4.45-0.08 (-1.77%)
Updated Nov 14, 2025
ABEO Price
$4.45
Fair Value Price
$0.01
Market Cap
$241.15M
52 Week Low
$3.93
52 Week High
$7.54
P/E
2.8x
P/B
1.41x
P/S
716.42x
PEG
N/A
Dividend Yield
N/A
Revenue
$400.00k
Earnings
$82.35M
Gross Margin
-22%
Operating Margin
21,650.75%
Profit Margin
20,587.5%
Debt to Equity
0.35
Operating Cash Flow
-$75M
Beta
0.83
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ABEO Overview
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ABEO's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important ABEO news, forecast changes, insider trades & much more!
ABEO News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ABEO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABEO ($4.45) is overvalued by 59,014.43% relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ABEO ($4.45) is not significantly undervalued (59,014.43%) relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ABEO is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ABEO due diligence checks available for Premium users.
Valuation
ABEO fair value
Fair Value of ABEO stock based on Discounted Cash Flow (DCF)
Price
$4.45
Fair Value
$0.01
Overvalued by
59,014.43%
ABEO ($4.45) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ABEO ($4.45) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ABEO is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ABEO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
2.8x
Industry
281.87x
Market
44.84x
ABEO is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ABEO is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ABEO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.41x
Industry
5.09x
ABEO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABEO's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.2M
Profit Margin
0%
ABEO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$231.1M
Liabilities
$59.9M
Debt to equity
0.35
ABEO's short-term assets ($216.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABEO's short-term assets ($216.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABEO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ABEO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.2M
Investing
-$64.6M
Financing
$5.2M
ABEO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ABEO vs Biotech Stocks
Abeona Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.